Main photo by HowToGym on Unsplash This article is for informational purposes only and is not intended to be a substitute for professional medical advice.
The American Diabetes Association strongly recommends the use of GLP-1 agonists for persons with type 2 diabetes who have already had a heart attack or who are at very high risk of heart disease, regardless of their A1C values
Trials using around 1,200mg/day in divided doses showed modest but consistent improvements in memory and executive function among patients with mild cognitive impairment, Alzheimers, or post-stroke deficits.32 Some reviews also note benefits for mood symptoms (apathy, anxiety) alongside cognition.32 For healthy individuals, the benefits are more nuanced
Frohman LA, Kineman RD
Cagrilintide's amylin mechanism (different pathway) How cagrilintide works: Amylin receptor agonist Long-acting weekly injection Investigational (not FDA approved) Different receptors than GIP/GLP-1 Amylin pathway effects: Very strong gastric emptying delay (stronger than GLP-1) Central appetite suppression (area postrema) Reduces meal frequency Suppresses glucagon Enhances satiety Cagrilintide monotherapy results: 10-12% average body weight loss Significant GI side effects (stronger gastric slowing) Currently in Phase 3 trials Not yet available pharmaceutically See our cagrilintide weight loss , cagrilintide dosing , and cagrilintide and semaglutide guides
Generic Liraglutide manufactured by Novo Nordisk who is also the manufacturer of reference product